4.20.5

Connecting via Winsock to STN

2/25/05 10/635,040a

Welcome to STN International! Enter x:x

Structure Search

LOGINID:SSSPTAAJP1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

400 C

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

nA/146-9/

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:01:01 ON 25 FEB 2005

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:01:09 ON 25 FEB 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 FEB 2005 HIGHEST RN 836595-43-8
DICTIONARY FILE UPDATES: 23 FEB 2005 HIGHEST RN 836595-43-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10635040a.str



chain nodes :
10 11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10 3-15 9-16 10-12 11-12 12-13 14-15 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-10 5-7 6-9 7-8 8-9 9-16 10-12 11-12

exact bonds :
3-15 12-13 14-15 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Hydrogen count :
10:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L1
SAMPLE SEARCH INITIATED 14:01:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:01:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 108 TO ITERATE

100.0% PROCESSED 108 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.01

L3 39 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 14:01:39 ON 25 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Feb 2005 VOL 142 ISS 10
FILE LAST UPDATED: 24 Feb 2005 (20050224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3
L4 9 L3

=> d L4 iib abs hitstr 1-9
'IIB' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels

```
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d L4 ibib abs hitstr 1-9

L4   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:         2004:80529  CAPLUS
DOCUMENT NUMBER:          140:133861
TITLE:                    ADP antagonists and ACAT inhibitors for treating
                          arteriosclerosis
INVENTOR(S):              Asai, Fumitoshi; Inaba, Toshimori; Ogawa, Taketoshi
PATENT ASSIGNEE(S):       Sankyo Company, Limited, Japan
SOURCE:                   PCT Int. Appl., 29 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     -------------------  ----   --------    ---------------------    --------
     WO 2004009119         A1    20040129    WO 2003-JP9108           20030717
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
```

co-pending
OIP
no common inventors
but shares
assignee

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2004051639 A2 20040219 JP 2003-275276 20030716

PRIORITY APPLN. INFO.: JP 2002-209165 A 20020718

AB A medicinal composition characterized in that an ADP receptor antagonist and an ACAT inhibitor, are administered either simultaneously or sep. at a definite interval. The medicinal composition is useful as a preventive or a remedy for arteriosclerosis or diseases derived from arteriosclerosis, such as ischemic heart disease, ischemic brain disease, and peripheral circulation failure in warm-blooded animals (in particular, humans). For example, pharmacol. activities of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt (II) were studied using rabbits and tablets containing I 10 mg and II 30 mg each were formulated.

IT **189198-30-9 189198-32-1**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ADP antagonists and ACAT inhibitors for treatment of arteriosclerosis and related disorders thereof)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9

CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:818314 CAPLUS
DOCUMENT NUMBER: 139:297051
TITLE: Medicinal composition comprising ACAT inhibitor and insulin resistance improving agent
INVENTOR(S): Inaba, Toshimori; Fujiwara, Toshihiko
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084572	A1	20031016	WO 2003-JP4296	20030403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481379	AA	20031016	CA 2003-2481379	20030403
BR 2003008871	A	20050104	BR 2003-8871	20030403
EP 1493448	A1	20050105	EP 2003-745697	20030403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004002365	A2	20040108	JP 2003-101076	20030404
PRIORITY APPLN. INFO.:			JP 2002-103134 A	20020405
			WO 2003-JP4296 W	20030403

AB It is intended to provide a medicinal composition for preventing or treating arteriosclerosis or diseases caused by arteriosclerosis which comprises an ACAT inhibitor and an insulin resistance improving agent. For example, tablets were formulated containing 5-[[4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione hydrochloride 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide hemisulfate 10, lactose 113, starch 25, and Mg stearate 2 mg/tablet.

IT **189198-30-9 608510-47-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal composition comprising ACAT inhibitor and insulin resistance improving agent)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



yes

RN 608510-47-0 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



yes

CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:202511 CAPLUS
DOCUMENT NUMBER: 138:226765
TITLE: Medicinal compositions containing angiotensin II receptor antagonists
INVENTOR(S): Sada, Toshio; Inaba, Toshimori
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 26 pp.

OSP

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020315	A1	20030313	WO 2002-JP8629	20020827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003146907	A2	20030521	JP 2002-246112	20020827
EP 1421953	A1	20040526	EP 2002-762874	20020827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012254	A	20041019	BR 2002-12254	20020827
US 2004198788	A1	20041007	US 2004-789340	20040226

PRIORITY APPLN. INFO.: JP 2001-257435 A 20010828
WO 2002-JP8629 W 20020827

AB Disclosed are medicinal compns. for administering an angiotensin II receptor antagonist and an ACAT inhibitor either at the same time or sep. at a certain interval. The compns. are effective for the prevention and treatment of arteriosclerosis and cardiac ischemia. For example, tablets were formulated containing olmesartan 50, N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide 10, lactose 113, starch 25, and Mg stearate 2 mg/each.

IT **189198-30-9**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing angiotensin II receptor antagonist and ACAT inhibitor)

RN 189198-30-9 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:792270 CAPLUS
DOCUMENT NUMBER: 137:310809

TITLE: Preparation of indolines as intermediates for preparation of ACAT inhibitors

INVENTOR(S): Tanabe, Hideo; Oyama, Yuzuru; Kiyota, Hiroshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002302481	A2	20021018	JP 2002-24876	20020201

PRIORITY APPLN. INFO.: JP 2001-26375 A 20010202
OTHER SOURCE(S): MARPAT 137:310809

GI



AB The compds. I (R1, R2 = lower alkyl; R3 = octyl) or their salts are prepared by deprotection of I (R1, R2 = lower alkyl; R3 = amino-protecting group) or their salts and octylation of I (R1, R2 = lower alkyl; R3 = H) or their salts. Carboxyindolines II (R1, R2 = lower alkyl) are prepared from I (R1, R2 = lower alkyl; R3 = octyl). N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was reacted with NaOMe in MeOH under reflux for 6 h, alkylated with octyl bromide in the presence of (iso-Pr)2NEt in xylene under reflux for 12 h, hydrolyzed in the presence of aqueous NaOH in PrOH under reflux for 15 h, and treated with H2SO4 in acetone-H2O mixture to give 83% N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate.

IT **189198-32-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolines as intermediates for preparation of ACAT inhibitors)

RN 189198-32-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9
CMF H2 O4 S



L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:716126 CAPLUS
DOCUMENT NUMBER: 137:252985
TITLE: Medicinal compositions containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors
INVENTOR(S): Inaba, Toshimori
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072147	A1	20020919	WO 2002-JP2311	20020312

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

JP 2002338496 A2 20021127 JP 2002-67841 20020313

PRIORITY APPLN. INFO.: JP 2001-72050 A 20010314

AB Disclosed are medicinal compns. for administering an ileal bile acid transporter inhibitor and a cholesterol acyltransferase (ACAT) inhibitor either at the same time or sep. at a certain interval. The effect of oral administration of both 4-[3-[(1-(3,5-difluorophenyl)ethylamino)-(4-methoxyphenyl)methyl]phenylamino]-3-hydroxy-3-cyclobutene-1,2-dione (I) and N-(1-octyl-5-carboxymethyl-4,6-dimethylindoline-7-yl)-2,2-dimethylpropaneamide (II) on blood serum triglyceride was prepared Also, a tablet containing I 50, II 30, lactose 368, corn starch 50, magnesium stearate 2 mg was prepared

IT **189198-30-9**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hypolipemic compns. containing bile acid transporter inhibitor and cholesterol acyltransferase inhibitors)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:615568 CAPLUS

DOCUMENT NUMBER: 137:169415

TITLE: Preparation of indoline derivatives as acyl-coenzyme A:cholesterol acyltransferase inhibitors

INVENTOR(S): Tomori, Hiroshi; Miyamoto, Hiroshi; Fukuhara, Hiroshi; Sonobe, Ryuichi; Miura, Motoko; Shimura, Kazuhiko; Fujimoto, Katsuhiko; Wakayama, Masakazu

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062758	A1	20020815	WO 2002-JP804	20020201
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2437134	AA	20020815	CA 2002-2437134	20020201
JP 2002302482	A2	20021018	JP 2002-24877	20020201

EP 1364942	A1	20031126	EP 2002-710441		20020201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
US 2004058979	A1	20040325	US 2003-635040		20030731
NO 2003003432	A	20031001	NO 2003-3432		20030801
PRIORITY APPLN. INFO.:			JP 2001-26374	A	20010202
			WO 2002-JP804	W	20020201

OTHER SOURCE(S): CASREACT 137:169415; MARPAT 137:169415

GI



I



II

our app

AB Novel intermediates such as I and II useful for synthesizing an indoline derivative having excellent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitory activity are prepared (R1 = an amino-protecting group; R2 and R3 = lower alkyl; and R4 = H or a carboxy-protecting group). Reaction of 1-acetyl-4,6-dimethylindoline with glyoxylic acid, hydrogenolysis with Pd-C and esterification with saturated HCl-EtOH solution, followed by nitration, hydrogenation, reaction with pivaloyl chloride, deacetylation, reaction with octyl bromide and base hydrolysis gave N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfuric acid salt.

IT **189198-32-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(indoline derivative useful for ACAT inhibitor and their preparation)

RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



CM 2

CRN 7664-93-9
CMF H2 O4 S



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:184896 CAPLUS
DOCUMENT NUMBER: 136:236854
TITLE: Medicinal compositions for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors
INVENTOR(S): Kohama, Takafumi; Inaba, Toshimori
PATENT ASSIGNEE(S): Sankyo Company, Ltd., Japan
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020009	A1	20020314	WO 2001-JP7438	20010829
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, SG, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001082541	A5	20020322	AU 2001-82541	20010829
CA 2420951	AA	20030228	CA 2001-2420951	20010829
EP 1314423	A1	20030528	EP 2001-961177	20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
NZ 524406	A	20040625	NZ 2001-524406	20010829
BR 2001013523	A	20040629	BR 2001-13523	20010829
RU 2246302	C2	20050220	RU 2003-105835	20010829
US 2002055533	A1	20020509	US 2001-943712	20010831
JP 2002145774	A2	20020522	JP 2001-262600	20010831
ZA 2003001543	A	20040609	ZA 2003-1543	20030225
NO 2003000946	A	20030408	NO 2003-946	20030228
US 2004092571	A1	20040513	US 2003-702930	20031105

PRIORITY APPLN. INFO.:

JP 2000-265082	A	20000901
US 2000-230601P	P	20000906
WO 2001-JP7438	W	20010829
US 2001-943712	B1	20010831

AB Disclosed are medicinal compns. for administering N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or its pharmacol. acceptable salt and an HMG-CoA reductase inhibitor either at the same time or sep. after a definite period of time. Blood lipid-lowering effect of oral administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate (I) 30 and pravastatin 3 mg/kg in hamsters was examined Also, tablet containing I 30, sodium pravastatin 10, lactose 408, corn starch 50, and magnesium stearate 2 mg was formulated.

IT **189198-32-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)

RN 189198-32-1 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



Yes

CM 2

CRN 7664-93-9
CMF H2 O4 S



IT **189198-30-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. for administration of N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and HMG-CoA reductase inhibitors)

RN 189198-30-9 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



Yes

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:113163 CAPLUS
DOCUMENT NUMBER: 136:167280
TITLE: Preparation of 5-carboxymethylindolines
INVENTOR(S): Kamiya, Shoji; Matsui, Hiroshi
PATENT ASSIGNEE(S): Kyoto Pharmaceutical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002047269	A2	20020212	JP 2000-233250	20000801

PRIORITY APPLN. INFO.: JP 2000-233250 20000801
OTHER SOURCE(S): CASREACT 136:167280; MARPAT 136:167280
GI



I

AB The compds. I (Y = CO2H; R1 = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R2, R3, R5 = H, lower alkyl, lower alkoxy; R4 = alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, etc.; A = alkylene; Z = CH2CH2, CH:CH) or their salts, as ACAT and lipid peroxidn. inhibitors, are prepared by carbamoylation of cyano compds. I (Y = cyano; R1 = protecting group; R2, R3, R5, A, Z = same as above), reaction of I (Y = CONH2; R1 = H; R2, R3, R5, A, Z = same as above) or their salts with R1X (R1 = same as above; X = leaving group), and carboxylation of I (Y = CONH2; R1 = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, etc.; R2, R3, R5, A, Z = same as above) or their salts. N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was treated with NaOH in MeOH under reflux for 20 h and alkylated with n-octyl bromide in DMF in the presence of K2CO3 and KI at 40° for 24 h to give N-(5-carbamoylmethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide, which was treated with NaOH in PrOH at 90-100° for 12 h to give 98% N-(5-carboxymethyl-4,6-dimethyl-1-octylindolin-7-yl)-2,2-dimethylpropanamide sulfate .

IT **189198-32-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of carboxymethylindolines)

RN 189198-32-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



yes

CM 2

CRN 7664-93-9
CMF H2 O4 S



L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:326877 CAPLUS
DOCUMENT NUMBER: 126:305540
TITLE: Preparation of benzene-fused heterocyclic derivatives as inhibitors of acyl-coenzyme A:cholesterol acyltransferase (ACAT) and medicinal use thereof
INVENTOR(S): Kamiya, Shoji; Shirahase, Hiroaki; Matsui, Hiroshi; Nakamura, Shohei; Wada, Katsuo
PATENT ASSIGNEE(S): Kyoto Pharmaceutical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9712860	A1	19970410	WO 1996-JP2852	19960930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
CA 2233842	AA	19970410	CA 1996-2233842	19960930
AU 9670977	A1	19970428	AU 1996-70977	19960930
AU 708571	B2	19990805		
EP 866059	A1	19980923	EP 1996-932060	19960930
EP 866059	B1	20011205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1203587	A	19981230	CN 1996-198670	19960930
CN 1097043	B	20021225		
BR 9610846	A	19990713	BR 1996-10846	19960930

on 1/49

JP 2968050	B2	19991025	JP 1996-514152		19960930
RU 2173316	C2	20010910	RU 1998-108605		19960930
IL 123939	A1	20011125	IL 1996-123939		19960930
AT 210116	E	20011215	AT 1996-932060		19960930
ES 2164920	T3	20020301	ES 1996-932060		19960930
PT 866059	T	20020328	PT 1996-932060		19960930
CZ 292632	B6	20031112	CZ 1998-996		19960930
TW 429250	B	20010411	TW 1996-85112125		19961004
NO 9801485	A	19980602	NO 1998-1485		19980401
US 6063806	A	20000516	US 1998-51202		19980403
HK 1015781	A1	20030822	HK 1999-100913		19990305
US 6200988	B1	20010313	US 2000-506839		20000218
CN 1361100	A	20020731	CN 2001-142957		20011130
PRIORITY APPLN. INFO.:			JP 1995-259082	A	19951005
			JP 1996-58018	A	19960314
			JP 1996-194331	A	19960724
			WO 1996-JP2852	W	19960930

OTHER SOURCE(S): MARPAT 126:305540

GI



I

AB Heterocyclic derivs. represented by general formula (I; one of R1, R2, and R5 = OH, CO2H, alkoxycarbonyl, NR9R10, or alkyl or alkenyl substituted by OH, acidic group, or NR9R10 and the others = H, lower alkyl or alkoxy; wherein R9, R10 = H, lower alkyl; one of R3 and R4 = NHCOR7 and the other = H, lower alkyl or alkoxy; wherein R7 = alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, NHR8; wherein R8 = alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl; R6 = alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, arylalkyl; Z = a linkage group required to form a 5- to 6-membered ring together with NR6 and C atoms of the benzene ring) or pharmaceutically acceptable salts thereof are prepared The compds. or pharmaceutically acceptable salts thereof show excellent effects of inhibiting ACAT and inhibiting the peroxidn. of lipids on mammals and thus are useful as ACAT inhibitors and lipid peroxidn. inhibitors. Namely, they are useful in the prevention and treatment of, for example, arteriosclerosis, hyperlipemia, arteriosclerotic lesions in association with diabetes, and ischemic diseases in brain and heart. Thus, N-(1-acetyl-5-chloromethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide was heated with AcOK in MeCN/DMF at 60° under stirring for 1 h, followed by saponification with NaOH in aqueous EtOH under reflux, to give N-(5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide, which was alkylated by 1-iodooctane in the presence of K2CO3 in DMF to give at 50° for 2 h N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolyl-7-yl)-2,2-dimethylpropanamide (II). II in vitro inhibited by 99.2% the production of cholesteryl oleate from [1-14C]oleoyl CoA in microsome fraction of rabbit small intestinal membrane and at 10 mg/kg per day for 3 days in vivo lowered by 57.1% a total serum cholesterol in rats fed with a high cholesterol diet.

IT **189198-30-9P 189198-31-0P 189198-32-1P 189198-33-2P 189198-34-3P 189198-49-0P**

189198-55-8P 189198-58-1P 189198-59-2P
189198-60-5P 189198-61-6P 189198-62-7P
189198-63-8P 189198-64-9P 189198-65-0P
189198-66-1P 189198-68-3P 189198-69-4P
189198-71-8P 189198-72-9P 189198-74-1P
189198-75-2P 189198-77-4P 189198-78-5P
189198-79-6P 189198-80-9P 189198-82-1P
189198-83-2P 189198-84-3P 189198-85-4P
189198-95-6P 189198-96-7P 189198-97-8P
189198-98-9P 189199-33-5P 189199-34-6P
189199-36-8P 189199-38-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzene-fused heterocyclic derivs. as inhibitor of acyl-CoA:cholesterol acyltransferase and lipid peroxidn. for disease therapy)

RN 189198-30-9 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



Yes

RN 189198-31-0 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monohydrochloride (9CI) (CA INDEX NAME)



Yes

RN 189198-32-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



yes

CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 189198-33-2 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 189198-30-9
CMF C25 H40 N2 O3



Yes

CM 2

CRN 7697-37-2
CMF H N O3



RN 189198-34-3 CAPLUS

CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 189198-49-0 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 189198-55-8 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(6-methylheptyl)- (9CI) (CA INDEX NAME)



RN 189198-58-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-nonyl- (9CI) (CA INDEX NAME)



homolog

RN 189198-59-2 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(7-methyloctyl)- (9CI) (CA INDEX NAME)



homolog (isomer)

RN 189198-60-5 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-(5-ethylheptyl)-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)





RN 189198-61-6 CAPLUS
CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 189198-62-7 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(8-methylnonyl)- (9CI) (CA INDEX NAME)



RN 189198-63-8 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-undecyl- (9CI) (CA INDEX NAME)



RN 189198-64-9 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(9-methyldecyl)- (9CI) (CA INDEX NAME)



RN 189198-65-0 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-dodecyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 189198-66-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethyl-1-(10-methylundecyl)- (9CI) (CA INDEX NAME)



RN 189198-68-3 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 189198-69-4 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxohexyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-71-8 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 189198-72-9 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxooctyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-74-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 189198-75-2 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxodecyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-77-4 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-1-heptyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 189198-78-5 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-79-6 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro-1-nonyl- (9CI) (CA INDEX NAME)



RN 189198-80-9 CAPLUS
CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-4,6-diethyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 189198-82-1 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-1-heptyl-2,3-dihydro-4,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 189198-83-2 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy-1-octyl- (9CI) (CA INDEX NAME)



RN 189198-84-3 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy-1-nonyl- (9CI) (CA INDEX NAME)



RN 189198-85-4 CAPLUS
CN 1H-Indole-5-acetic acid, 1-decyl-7-[(2,2-dimethyl-1-oxopropyl)amino]-2,3-dihydro-4,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 189198-95-6 CAPLUS
CN 1H-Indole-5-acetic acid, 1-heptyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)



RN 189198-96-7 CAPLUS
CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-octyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)



RN 189198-97-8 CAPLUS
CN 1H-Indole-5-acetic acid, 2,3-dihydro-6-methyl-1-nonyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)



RN 189198-98-9 CAPLUS
CN 1H-Indole-5-acetic acid, 1-decyl-2,3-dihydro-6-methyl-7-[(1-oxopentyl)amino]- (9CI) (CA INDEX NAME)



RN 189199-33-5 CAPLUS
CN 1H-Indole-5-acetic acid, 2,3-dihydro-7-[(3-methoxy-1-oxopropyl)amino]-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189199-34-6 CAPLUS
CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-7-[[3-(methylthio)-1-oxopropyl]amino]-1-octyl- (9CI) (CA INDEX NAME)



RN 189199-36-8 CAPLUS
CN 1H-Indole-5-acetic acid, 7-[(cyclohexylacetyl)amino]-2,3-dihydro-4,6-dimethyl-1-octyl- (9CI) (CA INDEX NAME)



RN 189199-38-0 CAPLUS
CN 1H-Indole-5-acetic acid, 2,3-dihydro-4,6-dimethyl-1-octyl-7-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.91	206.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.57	-6.57

STN INTERNATIONAL LOGOFF AT 14:02:27 ON 25 FEB 2005